Core Insights - ReShape Lifesciences Inc. announced a strategic headcount reduction aimed at saving over $750,000 annually, which represents approximately 23.4% of its payroll expenses [1][2] - The company is progressing towards finalizing a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys, with a special shareholder meeting scheduled for July 24, 2025, to vote on these transactions [1][2] Company Overview - ReShape Lifesciences is a leading provider of weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band System, which provides a minimally invasive treatment for obesity [3] - The company also has investigational products such as a vagal neuromodulation system for type 2 diabetes and the Obalon balloon technology for non-surgical weight loss [3] Strategic Focus - The company aims to maintain its core capabilities while enhancing operational efficiency through workforce reduction, ensuring that its sales and marketing team remains intact to drive patient leads via digital marketing [2] - ReShape is also focusing on international expansion efforts in Canada through a distribution agreement with Liaison Medical to launch the enhanced Lap-Band 2.0 FLEX [2]